Peptides for Telehealth Operators Post PCAC Meeting: What You Need to Know

• The FDA's Bulks List explained — Category 1, 2, and 3, and what to know post PCAC meeting decision
• The market opportunity: which patient populations are already seeking out peptides and which programs have natural demand
• How to stay compliant in a changing landscape
• Clinical considerations for operators: prescribing criteria, patient selection, monitoring, and retention

Whether you're evaluating peptides for your program or trying to understand what building compliantly actually requires, this session will give you the clearest picture available right now.